Skip to main content

Advertisement

SpringerLink
Log in

Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been regarded as a potential strategy for myeloid sarcoma (MS). The previous reports focused mainly on matched sibling donor (MSD) or matched unrelated donor (MUD) transplantation. There are no reports on haploidentical HSCT (haplo-HSCT) in MS. We retrospectively reviewed 14 MS patients who underwent haplo-HSCT. All patients achieved complete donor engraftment. The median time for neutrophil engraftment and platelet engraftment were 10 (12–21) days and 18 (8–31) days. The 100-day cumulative incidence of grade II–IV acute graft-versus-host disease (GVHD) and 3-year cumulative incidence of chronic GVHD were 37.7% (95%CI, 23.2–52.1%) and 35.7% (95%CI, 22.2–49.2%). Cytomegalovirus (CMV) reactivation was documented in 86% patients, and only one patient developed CMV pneumonia. Treatment-related mortality occurred in one (7%) patient. The 1- and 3-year cumulative incidence of relapse was 21.4% (95%CI, 11.8–31.1%) and 35.7% (95%CI, 22.4–49.0%). The probability of overall survival at 1 and 3 years was 71.4% (95%CI, 51.3–99.5%) and 64.3% (95%CI, 43.5–95.0%), respectively. The probability of disease-free survival at 1 and 3 years was 71.4% (95%CI, 51.3–99.5%) and 57.1% (95%CI, 36.3–89.9%), respectively. In conclusion, haplo-HSCT is a feasible method for patients with MS who have no MSD or MUD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 117:5019–5032

    Article  CAS  Google Scholar 

  2. Wilson CS, Medeiros LJ (2015) Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol 144:219–239

    Article  Google Scholar 

  3. Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, Djunic I, Mitrovic M, Tomin D (2013) Is there a “gold” standard treatment for patients with isolated myeloid sarcoma? Biomed Pharmacother 67:72–77

    Article  Google Scholar 

  4. Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, Bordigoni P, Vernant JP, Hunault M, Vigouroux S, Blaise D, Tabrizi R, Buzyn A, Socie G, Michallet M, Volteau C, Harousseau JL (2008) Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol 26:4940–4943

    Article  Google Scholar 

  5. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, Piccaluga PP, Agostinelli C, Asioli S, Novero D, Bisceglia M, Ponzoni M, Gentile A, Rinaldi P, Franco V, Vincelli D, Pileri A Jr, Gasbarra R, Falini B, Zinzani PL, Baccarani M (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 21:340–350

    Article  CAS  Google Scholar 

  6. Avni B, Koren-Michowitz M (2011) Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol 2:309–316

    Article  CAS  Google Scholar 

  7. Bakst RL, Tallman MS, Douer D, Yahalom J (2011) How I treat extramedullary acute myeloid leukemia. Blood. 118:3785–3793

    Article  CAS  Google Scholar 

  8. Avni B, Rund D, Levin M, Grisariu S, Ben-Yehuda D, Bar-Cohen S, Paltiel O (2012) Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. Hematol Oncol 30:34–40

    Article  Google Scholar 

  9. Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, Kanda Y, Nakaseko C, Yano S, Fujita H, Fujisawa S, Miyawaki S, Kanamori H, Okamoto S (2012) Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia. 26:2469–2473

    Article  CAS  Google Scholar 

  10. Wang HQ, Li J (2016) Clinicopathological features of myeloid sarcoma: report of 39 cases and literature review. Pathol Res Pract 212:817–824

    Article  Google Scholar 

  11. Reisner Y, Hagin D, Martelli MF (2011) Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 118:6006–6017

    Article  CAS  Google Scholar 

  12. Zuckerman T, Rowe JM (2007) Alternative donor transplantation in acute myeloid leukemia: which source and when? Curr Opin Hematol 14(2):152–161

    Article  Google Scholar 

  13. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23:3447–3454

    Article  Google Scholar 

  14. Kato S, Yabe H, Yasui M, Kawa K, Yoshida T, Watanabe A, Osugi Y, Horibe K, Kodera Y (2000) Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood. Bone Marrow Transplant 26:1281–1290

    Article  CAS  Google Scholar 

  15. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V, Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group (2008) A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 112:3574–3581

    Article  CAS  Google Scholar 

  16. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 107:3065–3073

    Article  CAS  Google Scholar 

  17. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP (2006) Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38:291–297

    Article  Google Scholar 

  18. Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, Liu D, Liu Q, Liu T, Jiang M, Ren H, Song Y, Sun Z, Wang J, Wu D, Zhou D, Zou P, Liu K, Huang X (2018) The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol 11:33

    Article  Google Scholar 

  19. Wang Y, Chen H, Chen J, Han M, Hu JD, Jiong Hu, Huang H, Lai Y, Liu D, Liu Q, Liu T, Jiang M, Ren H, Song Y, Sun Z, Wang C, Wang J, Wu D, Xu K, Zhang X, Xu L, Liu K, Huang X (2018) The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett 438:63–75

    Article  CAS  Google Scholar 

  20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 106:2912–2919

    Article  CAS  Google Scholar 

  21. Yan CH, Wang Y, Wang JZ et al (2016) Minimal residual disease- and graft-vs-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol 9:87

    Article  Google Scholar 

  22. Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers MED, Schultz KR, Vogelsang G, Pavletic S (2015) Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant 21:984–999

    Article  Google Scholar 

  23. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Jean Henslee-Downey P, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM (1997) IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97:855–864

    Article  CAS  Google Scholar 

  24. Liu D, Huang X, Liu K, Xu L, Chen H, Han W, Chen Y, Zhang X, Jiang Q (2008) Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant. 14:469–477

    Article  CAS  Google Scholar 

  25. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP (2009) Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 15:257–265

    Article  CAS  Google Scholar 

  26. Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474

    Article  Google Scholar 

  27. Lazzarotto D, Candoni A, Fili C et al (2017) Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey. Leuk Res 53:74–81

    Article  Google Scholar 

  28. Liang Y, Gao J, Wu D, Li S, Chen H, Ding L, Tong J, Xu Y (2017) Long-term remission following autologous hematopoietic cell transplantation in a patient with multiple nonleukemic myeloid sarcoma and a review of the literature. Acta Haematol 137:117–122

    Article  CAS  Google Scholar 

  29. Johansen S, Kollsete Gjelberg H, Ahmed AB, Bruserud O, Reikvam H (2018) Myeloid sarcoma after allogenic stem cell transplantation for acute myeloid leukemia: successful consolidation treatment approaches in two patients. Case Rep Oncol Med 2018:7697283

    PubMed  PubMed Central  Google Scholar 

  30. Chevallier P, Labopin M, Cornelissen J, Socie G, Rocha V, Mohty M, on behalf of the ALWP of EBMT (2011) Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the acute leukemia working party of the European group for blood and marrow transplantation. Haematologica. 96:1391–1394

    Article  Google Scholar 

  31. Chen Y, Wang Y, Xu LP, Liu KY, Chen H, Chen YH, Zhang XH, Wang FR, Han W, Wang JZ, Yan CH, Zhang YY, Sun YQ, Huang XJ (2015) Haploidentical stem cell transplantation in patients aged 50 yr and older with leukemia: similar outcomes compared to younger adults. Clin Transpl 29:523–530

    Article  Google Scholar 

  32. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Wu MQ, Wu DP, Huang XJ (2016) Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res 22:3467–3476

    Article  CAS  Google Scholar 

  33. Chang YJ, Huang XJ (2016) Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Semin Hematol 53:82–89

    Article  CAS  Google Scholar 

  34. Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, Ciceri F, Giebel S, Gorin NC, Savani BN, Schmid C, Nagler A (2017) Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working party of the European Society for blood and marrow transplantation. Haematologica. 102:224–234

    Article  CAS  Google Scholar 

  35. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 119:3256–3262

    Article  CAS  Google Scholar 

Download references

Funding

This work was partly supported by grants from the National Key Research and Development Program of China (2019YFC0840606) from the Ministry of Science and Technology, National Natural Science Foundation of China (Grant No. 82070189 & 81770189 & 81621001 & 81530046), the National Key Research and Development Program of China (2017YFA0104500),Peking University Clinical Scientist Program (BMU2019LCKXJ003), the Fundamental Research Funds for the Central Universities, the Science and Technology Project of Guangdong Province of China (Grant No. 2016B030230003), and the project of health collaborative innovation of Guangzhou city (no. 201704020214), Beijing Municipal Science & Technology Commission (No. Z191100006619054).

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematolo, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantationgy, National Clinical Research Center for Hematologic Disease, No.11, Xizhimen South Street, Xicheng District, Beijing, 100044, China

    Wen-Jing Yu, Yu-Qian Sun, Ting-Ting Han, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Chen-Hua Yan, Xiao-Jun Huang & Yu Wang

  2. Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China

    Pei-Pei Ye

  3. Peking-Tsinghua Center for Life Sciences, Beijing, China

    Xiao-Jun Huang

  4. Collaborative Innovation Center of Hematology, Peking University, Beijing, China

    Xiao-Jun Huang & Yu Wang

Authors
  1. Wen-Jing Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Qian Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ting-Ting Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pei-Pei Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lan-Ping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kai-Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chen-Hua Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiao-Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Wen-Jing Yu, Yu- Qian Sun, Xiao-Jun Huang, and Yu Wang conceived the study. Wen-Jing Yu, Ting-Ting Han, and Pei-Pei Ye analyzed and interpreted the data; Wen-Jing Yu and Pei-Pei Ye wrote the paper; Wen-Jing Yu, Yu- Qian Sun, Ting-Ting Han, and Pei-Pei Ye performed the statistical analyses; Wen-Jing Yu, Yu- Qian Sun, Ting-Ting Han, Pei-Pei Ye, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Chen-Hua Yan, and Xiao-Jun Huang included data of patients treated in their institutions. All authors reviewed the manuscript and contributed to the final draft.

Corresponding author

Correspondence to Yu Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the ethics committee of the institution.

Consent to participate

Informed consent for participation was obtained from all enrolled individuals.

Consent for publication

Informed consent for the publication of data was obtained from all enrolled individuals.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, WJ., Sun, YQ., Han, TT. et al. Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. Ann Hematol 100, 799–808 (2021). https://doi.org/10.1007/s00277-020-04383-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04383-x

Keywords

Search

Navigation